Edition:
India

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

27.60USD
12:48am IST
Change (% chg)

$0.24 (+0.88%)
Prev Close
$27.36
Open
$27.51
Day's High
$28.62
Day's Low
$27.32
Volume
130,692
Avg. Vol
296,833
52-wk High
$43.98
52-wk Low
$13.51

Select another date:

Tue, Jan 23 2018

BRIEF-Adamas Announces Proposed Public Offering Of Common Stock

* ADAMAS PHARMACEUTICALS INC SAYS IT PLANS TO OFFER $85 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

BRIEF-Adamas Announces U.S. Commercial Launch Of Gocovri, The First FDA-Approved Medication For Treatment Of Dyskinesia In Parkinson's Disease Patients

* ADAMAS ANNOUNCES U.S. COMMERCIAL LAUNCH OF GOCOVRI™ THE FIRST AND ONLY FDA-APPROVED MEDICATION FOR THE TREATMENT OF DYSKINESIA IN PARKINSON’S DISEASE PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Adamas Pharmaceuticals reports Q3 loss per share $1.04

* Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results

BRIEF-Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals

* Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals as of October 24 - SEC filing‍​ Source text (http://bit.ly/2zY2CVE) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Point72 Asset Management reports 5.1 pct passive stake in Adamas Pharma‍​

* Point72 Asset Management L.P reports a 5.1 percent passive stake in Adamas Pharmaceuticals Inc as of October 26, 2017 - SEC filing‍​ Source text : (http://bit.ly/2lnW6oI) Further company coverage:

BRIEF-Adamas Pharmaceuticals says FDA recognizes orphan drug exclusivity for GOCOVRI

* FDA recognizes orphan drug exclusivity for Adamas’ GOCOVRI Source text for Eikon: Further company coverage:

BRIEF-Adamas appoints Mardi C. Dier to its board of directors

* Adamas appoints Mardi C. Dier to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Adamas Pharmaceuticals says unit entered into amended and restated API supply agreement with Moehs Ibérica

* Adamas Pharmaceuticals says ‍on Oct 4, unit entered into amended and restated API supply agreement with Moehs Ibérica - SEC Filing

BRIEF-Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals‍​

* Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals as of August 29 - SEC filing ‍​ Source text: [http://bit.ly/2xSxczx] Further company coverage:

BRIEF-Adamas announces topline phase 1b data of ADS-4101 for the treatment of partial onset seizures in epilepsy

* Adamas announces topline phase 1b data of ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy

Select another date: